Abstract
An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Current Pharmaceutical Design
Title: Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants
Volume: 16 Issue: 31
Author(s): Erica Romualdi, Elena Rancan, Sergio Siragusa and Walter Ageno
Affiliation:
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Abstract: An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Export Options
About this article
Cite this article as:
Romualdi Erica, Rancan Elena, Siragusa Sergio and Ageno Walter, Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563329
DOI https://dx.doi.org/10.2174/138161210793563329 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Physiological Functions of Heat Shock Proteins
Current Protein & Peptide Science Clinical Assessment of Carotid Atherosclerosis Inflammation by Positron Emission Tomography
Current Molecular Medicine The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Long-Term Multimodal Therapy (Verapamil Associated with Propolis, Blueberry, Vitamin E and Local Diclofenac) on Patients with Peyronie's Disease (Chronic Inflammation of the Tunica Albuginea). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry The Use of Conformational Restriction in Medicinal Chemistry
Current Topics in Medicinal Chemistry Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology